A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 5, 2022

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Non-Hodgkin LymphomaNon-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma Refractory
Interventions
RADIATION

Bridging radiotherapy (BRT)

RT Part I. The target will be to complete the 9th fraction of radiotherapy (i.e., total of 27Gy) between days -12 and -8 Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy).

DRUG

Conditioning chemotherapy

Day -5 to -3: Patients will receive standard of care lymphodepleting chemotherapy

BIOLOGICAL

CAR T-cell product

Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER